Immunometabolism mRNA expression phenotypes and reprogramming of CD14 in T2DM with or without CVD
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110665 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Imen Bendaya und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Immunology and Microbiology Environmental and Carcinogenesis [IMEC], Faculty of Sciences of Bizerte, Zarzouna7021, University of Carthage, Bi…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND/AIM: Type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) have a significant impact on the expression of genes in peripheral blood mononuclear cells (PBMCs). The primary objective of this study was to investigate the role of two signaling pathways, STAT1/6, and two important modulators of immunometabolism, leptin and PPARs, in the development of T2DM with and without CVD. Furthermore, the study aimed to assess the correlation between these factors and the dynamics of CD14 in PBMCs. This research was conducted within the context of a growing body of literature on the complex pathophysiology of T2DM and its association with CVD. Prior studies have indicated that T2DM is characterized by an imbalance in immunometabolism and the involvement of various signaling pathways. MATERIALS AND METHODS: Blood samples were collected from a total of 47 subjects, including 7 healthy volunteers, 20 individuals diagnosed with diabetes and cardiovascular disease (D.CVD) and another 20 individuals diagnosed with diabetes only (D). PBMCs were isolated from these samples, and the expression levels of leptin, PPARγ, PPARα, and CD14 genes were measured using Real-Time PCR. RESULTS: The most relevant result showed that diabetic patients with CVD had significantly higher levels of leptin expression, which was positively correlated with STAT1 (r = 0.7497, p = 0.0001). On the other hand, diabetic patients without CVD had elevated PPARγ expression, which was strongly correlated with STAT6 (r = 0.8437, p = 0.0001). Interestingly, we found a significant increase in the PPARγ/ PPARα ratio in the D.CVD group compared to the D group (4.273 ± 0.9531; 7.52 ± 3.556, p = 0.0479). Moreover, CD14 expression was significantly reduced in this group compared to diabetic patients without CVD. CONCLUSION: These findings suggested that the immunometabolic imbalance in T2DM was driven by a STAT1/Leptin phenotype in diabetic patients with CVD and by a STAT6/PPARγ phenotype in diabetic patients without CVD. Taking into account STAT1/Leptin and STAT6/PPARγ profiling could help clinicians identify novel therapeutic targets for T2DM and other related diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Immunology and Microbiology Environmental and Carcinogenesis [IMEC], Faculty of Sciences of Bizerte, Zarzouna7021, University of Carthage, Bizerte, Tunisia. Electronic address: kefi.imen@gmail.com.
- Unit of Immunology and Microbiology Environmental and Carcinogenesis [IMEC], Faculty of Sciences of Bizerte, Zarzouna7021, University of Carthage, Bizerte, Tunisia; Department of Biology, Faculty of science of Gafsa ,Un…
- Department of Pathology, Salah Azaeiz Institute, Bab Saadoun 1006 Tunis, Tunis, Tunisia.
- Laboratory of Human Genetics, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
- Department of Cardiology, University Hospital Habib Bougatfa of Bizerte, Bizerte, Tunisia.
- Unit of Immunology and Microbiology Environmental and Carcinogenesis [IMEC], Faculty of Sciences of Bizerte, Zarzouna7021, University of Carthage, Bizerte, Tunisia.
Zitieren
APA
Bendaya, I., Ben Jemaa, A., Sahraoui, G., Kharrat, M., Sdiri, W., & Oueslati, R. (2023). Immunometabolism mRNA expression phenotypes and reprogramming of CD14 in T2DM with or without CVD. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110665
Vancouver
Bendaya I, Ben Jemaa A, Sahraoui G, Kharrat M, Sdiri W, Oueslati R. Immunometabolism mRNA expression phenotypes and reprogramming of CD14 in T2DM with or without CVD. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110665
BibTeX
@article{Bendaya2023,
author = {Bendaya, Imen and Ben Jemaa, Awatef and Sahraoui, Ghada and Kharrat, Maher and Sdiri, Wissem and Oueslati, Ridha},
title = {Immunometabolism mRNA expression phenotypes and reprogramming of CD14 in T2DM with or without CVD},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110665}
}
EUVIMED